May 31, 2019

WATCH: Domagrozumab as a Potential Treatment for Duchenne – Webinar Recording

On May 22, 2019, Pfizer Inc. joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the primary safety and efficacy results from the Phase 2 clinical trial. Additional…

Learn More

October 15, 2018

WATCH: Is Myostatin Still a Potential Therapeutic Target? – Webinar Recording

Myostatin is a negative regulator of muscle growth – a protein that stops muscle building and doesn’t let them get too big, as part of the natural regeneration process. In other words, if we can…

Learn More

August 30, 2018

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne

We are deeply disappointed to learn that Pfizer is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne: a Phase 2 safety and efficacy study (B5161002) and an open-label extension study…

Learn More